Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jul 15, 2021; 13(7): 673-683
Published online Jul 15, 2021. doi: 10.4251/wjgo.v13.i7.673
Published online Jul 15, 2021. doi: 10.4251/wjgo.v13.i7.673
Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma
Pu Chen, Qiong-Xuan Fang, Dong-Bo Chen, Hong-Song Chen, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, Peking University People’s Hospital, Beijing 100044, China
Author contributions: Chen P, Fang QX, and Chen DB contributed equally to this work; Chen P and Fang QX wrote the paper; Chen DB collected and analyzed the data; Chen HS designed the study.
Supported by National Key Sci-Tech Special Project of China , No. 2018ZX10302207 .
Conflict-of-interest statement: The authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hong-Song Chen, PhD, Senior Scientist, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, Peking University People’s Hospital, No. 11 Xizhimen South Street, Beijing 100044, China. chenhongsong@bjmu.edu.cn
Received: February 20, 2021
Peer-review started: February 20, 2021
First decision: March 29, 2021
Revised: April 6, 2021
Accepted: June 17, 2021
Article in press: June 17, 2021
Published online: July 15, 2021
Peer-review started: February 20, 2021
First decision: March 29, 2021
Revised: April 6, 2021
Accepted: June 17, 2021
Article in press: June 17, 2021
Published online: July 15, 2021
Core Tip
Core Tip: In previous studies of tumor immunotherapy strategies targeting neoantigens, the unique events generating the neoantigens in each tumor have not been well studied. In this paper, we analyze the generation events of hepatocellular carcinoma (HCC) neoantigens. We also provide some methods for screening and identifying HCC neoantigens and clinical strategies for exploiting HCC neoantigens.